BioCryst Pharmaceuticals BCRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's operating cash flow?
- BioCryst Pharmaceuticals (BCRX) reported operating cash flow of -$61.79M in Q1 2026.
- How has BioCryst Pharmaceuticals's operating cash flow changed year-over-year?
- BioCryst Pharmaceuticals's operating cash flow decreased by 124.6% year-over-year, from -$27.52M to -$61.79M.
- What is the long-term trend for BioCryst Pharmaceuticals's operating cash flow?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's operating cash flow has grown at a 34.7% compound annual growth rate (CAGR), from -$142.16M to $347.37M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.